220 related articles for article (PubMed ID: 37204477)
1. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
Rahman N; Artiaga JCM; Bouras K; Luis J; Rees A; Westcott M
J Ophthalmic Inflamm Infect; 2023 May; 13(1):27. PubMed ID: 37204477
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Vukojević M; Vukojevic N; Vuković A; Rupčić B; Blažević M; Blažević A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):229-231. PubMed ID: 38651852
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Patients with Vogt-Koyanagi-Harada Disease from the First-line Antimetabolites for Steroid-sparing Treatment Uveitis Trial.
Acharya NR; Rathinam SR; Thundikandy R; Kanakath A; Balamurugan S; Vedhanayaki R; Gonzales JA; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Arellanes-Garcia L; Coyne A; Porco TC; Shantha JG;
Am J Ophthalmol; 2024 Jun; ():. PubMed ID: 38909740
[TBL] [Abstract][Full Text] [Related]
6. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset.
Ei Ei Lin Oo ; Chee SP; Wong KKY; Hla Myint Htoon
Am J Ophthalmol; 2020 Dec; 220():37-44. PubMed ID: 32738228
[TBL] [Abstract][Full Text] [Related]
8. New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease.
Abu El-Asrar AM; Van Damme J; Struyf S; Opdenakker G
Front Med (Lausanne); 2021; 8():705796. PubMed ID: 34869409
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
10. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
11. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.
Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M
Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
13. EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.
Park HS; Park HY; Lee CS; Lee SC; Lee JH
Retina; 2022 Dec; 42(12):2361-2367. PubMed ID: 36394890
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.
Lodhi SA; Reddy JL; Peram V
Clin Ophthalmol; 2017; 11():1399-1406. PubMed ID: 28848322
[TBL] [Abstract][Full Text] [Related]
15. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.
Herbort CP; Abu El Asrar AM; Takeuchi M; Pavésio CE; Couto C; Hedayatfar A; Maruyama K; Rao X; Silpa-Archa S; Somkijrungroj T
Int Ophthalmol; 2019 Jun; 39(6):1419-1425. PubMed ID: 29948499
[TBL] [Abstract][Full Text] [Related]
16. Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.
Accorinti M; Saturno MC; Iannetti L; Manni P; Mastromarino D; Pirraglia MP
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806916
[TBL] [Abstract][Full Text] [Related]
17. Early resolution of subretinal fluid without high-dose corticosteroids in a pregnant patient with Vogt-Koyanagi-Harada disease: a case report.
Sugita K; Mizumoto K; Kato N; Zako M
J Ophthalmic Inflamm Infect; 2015; 5():20. PubMed ID: 26140057
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
Guo K; Xu X; Yang F; Wang K; Zhang X
Ocul Immunol Inflamm; 2024 May; ():1-11. PubMed ID: 38709230
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area.
Herbort CP; Tugal-Tutkun I; Khairallah M; Abu El Asrar AM; Pavésio CE; Soheilian M
Int Ophthalmol; 2020 Sep; 40(9):2423-2433. PubMed ID: 32418076
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
